Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Amortization - Intangibles: 2018-2024

Historic Amortization - Intangibles for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to $36.0 million.

  • Akebia Therapeutics' Amortization - Intangibles changed negligibly% to $9.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $36.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of FY2024, Akebia Therapeutics' Amortization - Intangibles stood at $36.0 million, which was down 0.00% from $36.0 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Amortization - Intangibles ranged from a high of $36.0 million in FY2021 and a low of $32.6 million during FY2020.
  • In the last 3 years, Akebia Therapeutics' Amortization - Intangibles had a median value of $36.0 million in 2024 and averaged $36.0 million.
  • Per our database at Business Quant, Akebia Therapeutics' Amortization - Intangibles declined by 10.40% in 2020 and then increased by 10.50% in 2021.
  • Over the past 5 years, Akebia Therapeutics' Amortization - Intangibles (Yearly) stood at $32.6 million in 2020, then increased by 10.50% to $36.0 million in 2021, then remained steady at $36.0 million in 2022, then remained steady at $36.0 million in 2023, then remained steady at $36.0 million in 2024.